Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index; 9 of the 48 sources its claims cite were checked for support.

Predicting relapse after antidepressant withdrawal – a systematic review

Open access
Berwian, I. M., Walter, H., Seifritz, E., Huys, Q. J. M. · 2017 · Psychological Medicine

Abstract

A substantial proportion of the burden of depression arises from its recurrent nature. The risk of relapse after antidepressant medication (ADM) discontinuation is high but not uniform. Predictors of individual relapse risk after antidepressant discontinuation could help to guide treatment and mitigate the long-term course of depression. We conducted a systematic literature search in PubMed to identify relapse predictors using the search terms '(depress* OR MDD*) AND (relapse* OR recurren*) AND (predict* OR risk) AND (discontinu* OR withdraw* OR maintenance OR maintain or continu*) AND (antidepress* OR medication OR drug)' for published studies until November 2014. Studies investigating predictors of relapse in patients aged between 18 and 65 years with a main diagnosis of major depressive disorder (MDD), who remitted from a depressive episode while treated with ADM and were followed up for at least 6 months to assess relapse after part of the sample discontinued their ADM, were included in the review. Although relevant information is present in many studies, only 13 studies based on nine separate samples investigated predictors for relapse after ADM discontinuation. There are multiple promising predictors, including markers of true treatment response and the number of prior episodes. However, the existing evidence is weak and there are no established, validated markers of individual relapse risk after antidepressant cessation. There is little evidence to guide discontinuation decisions in an individualized manner beyond overall recurrence risk. Thus, there is a pressing need to investigate neurobiological markers of individual relapse risk, focusing on treatment discontinuation.

Overview

CoChat Summary

TL;DR

This systematic review found only 13 studies based on nine separate datasets that examined predictors of relapse after antidepressant discontinuation, and no established, validated individual marker emerged. Promising signals include true drug response pattern and number of prior episodes, but the evidence remains weak and insufficient to guide individualized discontinuation decisions beyond overall recurrence risk.

Key findings

  • The PubMed search retrieved 899 studies; 61 were read in full text, and 13 studies based on nine separate datasets met inclusion criteria. No study used neuroimaging predictors, no naturalistic study was identified, and all patients who discontinued received placebo.
  • True drug response pattern was the most consistent signal: Stewart et al. (1998) found discontinuation increased relapse in likely true drug responders (log-rank = 22.37, p < 0.001 for 12 v. 26 weeks; log-rank = 8.23, df = 1, p < 0.005 for 26 v. 50 weeks), and Nierenberg et al. (2004) found relapse risk after discontinuation was larger in true than placebo response patterns (log-rank = 4.87, df = 1, p = 0.027). McGrath et al. (2006) failed to find a significant response-pattern × discontinuation interaction.
  • Number of prior episodes did not significantly interact with treatment in four studies. In Keller et al. (1998), placebo relapse was 40% in first-episode patients v. 55% in recurrent patients, while sertraline relapse was 29% v. 24%; the treatment × prior episode interaction was not significant (p = 0.25).
  • Other isolated signals included high anxiety increasing relapse in the discontinuation group (risk ratio = 1.632, p = 0.013; relapse rates 53.3% v. 40.7% for high v. low anxiety) but not the continuation group (28.5% v. 27.2%) in Joliat et al. (2004), and somatic pain interacting with treatment in Fava et al. (2009; hazard ratios 0.62 v. 0.25 in high- v. low-pain groups, p = 0.048).

Methods

  • Systematic PubMed search until November 2014 using terms combining depression/MDD, relapse/recurrence, predictors/risk, discontinuation/withdrawal/maintenance/continuation, and antidepressant/medication/drug; 899 records were retrieved, with Cohen’s κ = 0.75 for abstract inter-rater agreement.
  • Inclusion criteria: patients aged 18–65 years with a main diagnosis of MDD, remitted from a depressive episode while treated with antidepressant medication, followed for at least 6 months to assess relapse, with part of the sample discontinuing antidepressant medication; original research reporting relapse predictors in the discontinuation group alone or a treatment × predictor interaction. Exclusion criteria included anonymous prescription-record data and confounds with psychotherapy.
  • The review narratively synthesized 13 studies from nine datasets; no meta-analysis was performed, and the authors did not formally evaluate study quality because results were overall weak.

Limitations

  • The authors state that only one database was searched, full-text access was not available for all relevant studies, and eligible studies may have been missed; reporting/positive bias is possible because positive findings are more likely to be cited and to appear in titles used for initial screening.
  • The authors state that they did not formally evaluate the quality of included studies, and they excluded psychotherapy studies to avoid confounding, although psychotherapy is known to prevent relapse.
  • Evident from the text: the evidence base is very small (13 studies, nine datasets), sample sizes were often small, interaction testing and multiple-comparison corrections were inconsistent, and there was heterogeneity in definitions, relapse criteria, follow-up, and medications; the authors conclude the field is insufficient to draw either positive or negative conclusions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1017/s0033291716002580

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. Relapse risk after placebo-controlled randomized antidepressant treatment discontinuation. Some risk factors may identify patients who benefit from antidepressant medication due to effects driven by discontinuation (a), or continuation arms (c). In the former case, the risk score should differ between relapsers and non-relapsers in the discontinuation arm (b), while in the latter case it should differ in the continuation arm (d). Other risk factors may identify mixed effects.
Fig. 1. Relapse risk after placebo-controlled randomized antidepressant treatment discontinuation. Some risk factors may identify patients who benefit from antidepressant medication due to effects driven by discontinuation (a), or continuation arms (c). In the former case, the risk score should differ between relapsers and non-relapsers in the discontinuation arm (b), while in the latter case it should differ in the continuation arm (d). Other risk factors may identify mixed effects.CC BY · PubMed Central
Fig. 2. Consolidated Standards of Reporting Trials (CONSORT) diagram depicting number of studies excluded at each step. Exclusion and inclusion criteria are not mutually exclusive. Not all criteria met by each study might be listed in the second box on the right-hand side, since it was not always possible to determine all criteria from the abstract.
Fig. 2. Consolidated Standards of Reporting Trials (CONSORT) diagram depicting number of studies excluded at each step. Exclusion and inclusion criteria are not mutually exclusive. Not all criteria met by each study might be listed in the second box on the right-hand side, since it was not always possible to determine all criteria from the abstract.CC BY · PubMed Central

Verification

Claims the paper makes

9 Valid · 1 Not valid · 45 Not checked · 47 Own results and interpretations

52 more claims

Create a free account to see all 102 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 29
  • Probably not a substantial claim. 21
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 55 references

Research works printed but not linked: 2

  1. 2000, Diagnostic and Statistical Manual Text Revision (DSM-IV-TR)
  2. 2010, Depression: The Treatment and Management of Depression in Adults (Updated Edition)

Cited by

See all 93

Metadata

Authors
Berwian, I. M., Walter, H., Seifritz, E., & Huys, Q. J. M.
Affiliations
  • University of Zurich (CH)
  • Charité – Universitätsmedizin Berlin (DE)
Corresponding author
Berwian, I. M.
Venue
Psychological Medicine
Published
2016-10-27
Volume
47
Issue
3
Pages
426-437
ISSN
  • 0033-2917 (ISSN-L)
  • 1469-8978
OpenAlex
W2546247999
Cited by
93
References
55
Citations by year
2026: 3 · 2025: 8 · 2024: 12 · 2023: 8 · 2022: 5 · 2021: 11 · 2020: 17 · 2019: 10 · 2018: 8 · 2017: 11
FWCI
1.10
Type
journal article
Language
en
Open access
Locations
  • Psychological Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
  • Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • ETH Zürich Research Collection
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030L_153449/1)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
antidepressant discontinuation, recurrence prediction, major depressive disorder, relapse risk factors, treatment response biomarkers, neurobiological markers, individualized treatment decision-making
MeSH terms
Adolescent, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Humans, Middle Aged, Outcome Assessment, Health Care, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predicting relapse after antidepressant withdrawal – a systematic review. https://app.cochat.ai/papers/10.1017/s0033291716002580
The paper
Berwian, I. M., Walter, H., Seifritz, E., & Huys, Q. J. M. (2017). Predicting relapse after antidepressant withdrawal – a systematic review. Psychological Medicine. https://doi.org/10.1017/s0033291716002580

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.